

administering an anti-ligand for binding to said first ligand, wherein the anti-ligand is an anti-ligand selected from the group consisting of avidin, streptavidin, neutravidin, and derivatives and analogs thereof;

administering a second agent comprising von Willebrand factor, said second agent specifically binds platelets, said second agent comprising a second ligand for binding said anti-ligand, and allowing the second agent to bind to the binding agent;  
binding platelets on the second agent;  
inducing activation of the platelets; and thereby  
allowing a thrombus to form.

CANCEL claims 14, 17-18, and 29-39, without prejudice to re-file.

#### REMARKS

This response is in response to the office action mailed 20 May 2002. Entry of the above is respectfully requested.

Following the entry of this amendment, claim 12 is pending. In view of the amendments set out above and the following remarks, reconsideration is respectfully requested. Applicants attach a red-line copy of the claims that reflect the amendments to the claims.

#### The paragraph 5 rejection

Claims 12, 14, 17-18, and 29-39 have been rejected under 35 U.S.C. §112, second paragraph, for indefiniteness in the use of the word "component." The rejection further states that substituting "agent" for "component" would overcome this rejection.